Pharmacology
MDMA drives release of serotonin, norepinephrine, and dopamine, and increases oxytocin signaling. The resulting state is characterized by reduced fear response and increased interpersonal openness rather than perceptual change.
Entactogen · Monoamine releaser
MDMA
3,4-Methylenedioxymethamphetamine, an entactogen studied primarily as an adjunct to psychotherapy for post-traumatic stress disorder.
History & context
First synthesized in 1912 and later used by some therapists in the late 1970s and early 1980s, MDMA was scheduled in 1985 following widespread recreational use.
Research landscape
Phase 3 trials of MDMA-assisted therapy for PTSD have reported substantial symptom reduction, alongside continued regulatory and methodological debate.
Risks
Hyperthermia, hyponatremia, cardiovascular strain, and post-use mood disturbance. Contaminated illicit supply remains a major source of harm.
Educational reference only. Nothing here is medical advice or a recommendation to use any substance.
More compounds